Insider Trading February 24, 2026

Vicarious Surgical President Sells Small Stake to Cover RSU Taxes as Company Lowers 2025 Cash Burn

Adam David Sachs disposed of 942 Class A shares on Feb. 20, 2026; company strikes software partnership and trims projected 2025 cash burn

By Sofia Navarro RBOT
Vicarious Surgical President Sells Small Stake to Cover RSU Taxes as Company Lowers 2025 Cash Burn
RBOT

Adam David Sachs, president of Vicarious Surgical Inc. (NASDAQ: RBOT), sold 942 shares of Class A common stock on February 20, 2026, for $1,966 to meet tax-withholding obligations tied to vested restricted stock units. The sale occurred at a weighted average price of $2.0878, with prices ranging from $1.845 to $2.290. Following the transaction, Sachs retains direct ownership of 46,943 shares. The company is trading at $2.01 amid marked volatility and has reported a strategic partnership to outsource significant software development work while lowering its 2025 cash burn guidance to about $45 million.

Key Points

  • Insider sale: Adam David Sachs sold 942 shares on Feb. 20, 2026, for $1,966 to meet tax withholding obligations tied to vested RSUs.
  • Operational update: Vicarious Surgical engaged a global digital engineering and software development partner to take on substantive software responsibilities, including control systems and visualization.
  • Financial guidance: The company trimmed its 2025 cash burn estimate to approximately $45 million from $50 million and plans to issue 2026 cash burn guidance before year-end.

Transaction details

On February 20, 2026, Adam David Sachs, president of Vicarious Surgical Inc. (NASDAQ: RBOT), sold 942 shares of the company's Class A common stock for a total of $1,966. The shares changed hands at a weighted average price of $2.0878, with individual transaction prices reported between $1.845 and $2.290. Company filings indicate the disposition was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units, in accordance with Vicarious Surgical Inc.'s equity incentive plan.

Ownership and market context

After the sale, Sachs still directly owns 46,943 shares of Vicarious Surgical. At the time the transaction was reported, the stock was trading at $2.01. The share price has shown significant short-term movement - gaining 22% over the prior week - while remaining down 84% over the preceding year, underscoring pronounced volatility in the company's market value.

Corporate developments

Separately, Vicarious Surgical announced a strategic collaboration with a global digital engineering and software development services firm. Under the agreement, the partner will assume sizable software development responsibilities that the company had previously handled internally, including work on control systems and visualization. The arrangement is presented as part of the company’s efforts to reshape its operating model.

Financial outlook and operational reset

Vicarious Surgical also revised its projected cash burn for 2025, lowering the figure to approximately $45 million from an earlier estimate of $50 million. Company statements attribute the $5 million reduction to disciplined cost management measures implemented as part of an ongoing operational reset. Management has indicated it will provide guidance for the company’s expected cash burn in 2026 before the end of this year.

Valuation note

According to InvestingPro, the company appears undervalued at current levels, with a more detailed analysis available in a Pro Research Report.


Summary of facts

  • Adam David Sachs sold 942 Class A shares on February 20, 2026, totaling $1,966.
  • Sale executed at a weighted average price of $2.0878; individual prices ranged $1.845 to $2.290.
  • Transaction was made to cover tax withholding for vested restricted stock units under the company equity incentive plan.
  • After the sale, Sachs owns 46,943 shares directly.
  • Vicarious Surgical stock traded at $2.01, up 22% over the prior week and down 84% year over year.
  • The company announced a strategic outsourcing partnership for software development and lowered its 2025 cash burn guidance to about $45 million from $50 million.

Risks

  • Stock volatility - The share price has swung sharply, rising 22% in the prior week while falling 84% over the last year, reflecting market volatility that affects investors and market liquidity - impacts the equities and investor sentiment sectors.
  • Outsourcing execution - Transferring major software development tasks to an external partner introduces execution and integration risk related to control systems and visualization work - impacts software development and medtech operations.
  • Future cash-burn uncertainty - While 2025 guidance was lowered, the company has not yet provided 2026 cash-burn guidance, leaving financial runway and capital planning uncertain - impacts corporate finance and capital markets.

More from Insider Trading

Murphy USA SVP Disposes $1.1 Million in Stock; Company Posts Mixed Q4 Results Feb 24, 2026 Innospec Director Executes Options and Sells 1,030 Shares Worth $84,296 Feb 24, 2026 Innospec Director Larry Padfield Disposes of 1,030 Shares, Exercises Options and Sees RSUs Vesting Feb 24, 2026 Honeywell Director Disposes $1.4M in Stock; Exercises Options in Same Session Feb 24, 2026 Applied Materials Director Disposes $1.49M in Shares as Stock Nears 52-Week High Feb 24, 2026